PharmaCyte's Pancreatic Cancer Treatment Approval Odds and Timing Just Moved Much Higher

Oct 26, 2015, 09:15 ET from Goldman Small Cap Research

BALTIMORE, October 26, 2015 /PRNewswire/ --

Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new sponsored research article on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research update, along with disclosures and disclaimers, or to download it and previous reports, updates, and articles in their entirety, please visit  

In the update, analyst Rob Goldman notes that major industry and company news released last week should take investor sentiment to a new level regarding the potential of FDA approval for PharmaCyte's pancreatic cancer treatment for patients with locally advanced pancreatic cancer.  

According to Goldman, "Merrimack Pharmaceuticals was awarded FDA approval last week for its treatment designed for patients with metastatic pancreatic cancer. Considering its poor side effect profile, associated warning label and incrementally positive median survival rate, it appears that the bar has been lowered by the FDA for priority approval of pancreatic cancer therapies which serves as a huge positive for PharmaCyte timing-wise as well. Plus, both Merrimack and PharmaCyte use an encapsulation approach to treatment, which is yet another plus in PharmaCyte's corner."

"Hall of Fame Clinical Research Organizations and oncologists collaborated on the future PharmaCyte trial design and protocols which includes conducting the trial in the U.S.   Separately, these well-regarded CRO and oncology partners provide the Company with unique insight and experience into what it takes to initiate and execute a pancreatic cancer therapy trial that has the best possible chance for success. Therefore, their inclusion in the trial design and management process should be viewed as a meaningful positive, noted Goldman."  

Goldman continued, "In its upcoming trial, the Company's treatment is being positioned as an expansion of the current gold standard of care or as a consolidation therapy, rather than a front-line therapy that goes head-to-head against the gold standard.  By positioning PharmaCyte as the next or last stage therapy may be the fastest route to approval, as there is no truly effective therapy for patients at this stage that can materially extend survival rates and improve their quality of life. Moreover, as a consolidation therapy PharmaCyte plays to the strengths of the Cell-in-a-Box[®  ]+ low-dose ifosfamide chemotherapy, given the very strong one-year survival rates and no side effects in its first clinical trial, and could mirror Merrimack's approval timing and sales potential, if approved."  

About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

This press release contains excerpts of our most recently published sponsored research report on PharmaCyte Biotech, Inc.  The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from PharmaCyte Biotech Inc. ("the Company") authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission

Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.

A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only.  Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit In 2015, Goldman Small Cap Research has been compensated by a third party in the amount of $22,000 for investment research services that includes the publication of research reports, updates, and a series of articles.

About PharmaCyte Biotech.: PharmaCyte Biotech Inc. (OTCQB - PMCB) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. More information on PMCB can be found at

Goldman Small Cap Research
Rob Goldman, Analyst

SOURCE Goldman Small Cap Research